[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368254-105":59,"doc-detail-368254-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","trends-in-cervical-precancers-identified-through-population-based-surveillance-human-papillomavirus-vaccine-impact-monitoring-project-five-sites-united-states-20082022","Trends in Cervical Precancers Identified Through Population-Based Surveillance - Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008–2022","","Human papillomavirus (HPV) vaccination is increasingly used in the United States, and the CDC monitored trends in precancerous cervical lesions (CIN2+ and CIN3+) since 2008 through the five-site Human Papillomavirus Vaccine Impact Monitoring Project. From 2008–2022, CIN2+ rates among screened women aged 20–24 years decreased by 79%, while CIN3+ decreased by 80%. Among screened women aged 25–29 years, CIN3+ decreased by 37%, supporting vaccination impact and routine age recommendations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/trends-in-cervical-precancers-identified-through-population-based-surveillance-human-papillomavirus-vaccine-impact-monitoring-project-five-sites-united-states-20082022/368254/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/trends-in-cervical-precancers-identified-through-population-based-surveillance-human-papillomavirus-vaccine-impact-monitoring-project-five-sites-united-states-20082022/368254.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What surveillance outcome does the HPV-IMPACT project track for cervical cancer prevention impact?","Question",{"text":112,"@type":113},"It tracks the incidence of precancerous cervical lesions, defined as CIN2+ (CIN grades 2–3 and adenocarcinoma in situ) and CIN3+ (CIN grade 3 and AIS).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What were the reported changes in CIN2+ and CIN3+ rates from 2008 to 2022 for ages 20–24?",{"text":117,"@type":113},"Among screened women aged 20–24, rates decreased by 79% for CIN2+ and by 80% for CIN3+ during 2008–2022.",{"name":119,"@type":110,"acceptedAnswer":120},"Which age group showed a decline in CIN3+ rates from 2008 to 2022 in addition to the 20–24 group?",{"text":121,"@type":113},"Women aged 25–29 years showed a 37% decrease in CIN3+ rates during 2008–2022.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368254,1790286933,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Morbidity and Mortality Weekly Report  \nTrends in Cervical Precancers Identified Through Population-Based Surveillance—Human Papillomavirus Vaccine Impact Monitoring Project,  \nFive Sites, United States, 2008–2022  \nJulia W. Gargano, PhD 1; Ruth Stefanos, MD1,2; Rebecca M. Dahl, MPH 1; Jessica L. Castilho, MD3,4; Erica A. Bostick, MD5; Linda M. Niccolai, PhD6; Ina U. Park, MD7; Sheelah Blankenship, MS4; Monica M. Brackney, MS6; Kameny Chan, MPH8; Emily L. Delikat, MPH4; Sara Ehlers, MPH8; Kimberly Gonzalez Barrera, MPH9; RaeAnne Kurtz5; James I. Meek, MPH6; Erin Whitney, MPH9; Marissa Vigar, MPH 1; Elizabeth R. Unger, MD, PhD 10; Lauri E. Markowitz, MD 1; HPV-IMPACT Working Group  \nAbstract  \nIn 2006, human papillomavirus (HPV) vaccine was first recommended in the United States to prevent cancers and other diseases caused by HPV; vaccination coverage increased steadily through 2021, and increasing numbers of young women had received HPV vaccine as children or adolescents. Since 2008, CDC has monitored incidence of precancerous lesions (cervical intraepithelial neoplasia [CIN] grades 2–3 and adenocarcinoma in situ [AIS], collectively CIN2+), which are detected through cervical cancer screening and can be used as an intermediate outcome for monitoring vaccination impact, via the five-site Human Papillomavirus Vaccine Impact Monitoring Project. This analysis describes trends in incidence ofCIN2+ and CIN3+(i.e., CIN grade 3 and AIS) lesions during 2008–2022. Among women aged 20–24 years who were screened for cervical cancer, rates during 2008–2022 decreased for CIN2+ by 79%, and for CIN3+ by 80% . In the same period, CIN3+ rates among screened women aged 25–29 years decreased by 37%. These data are consistent with considerable impact of HPV vaccination for preventing cervical precancers among women in the age groups most likely to have been vaccinated, and support existing recommendations to vaccinate children at the routinely recommended ages as a cancer prevention measure.  \nIntroduction  \nHuman papillomavirus (HPV) causes approximately 10,800 cervical cancers in the United States each year; cervical cancer is the most common HPV-attributable cancer among women ( 1) . HPV-attributable cancers take many years to develop (median age at diagnosis = 50 years),* whereas screendetected cervical precancers (cervical intraepithelial neoplasia [CIN] grades 2–3 and adenocarcinoma in situ [AIS], collectively CIN2+) can develop within a few years after infection (2) . Screening with the Papanicolaou (Pap) test and treatment of precancerous abnormalities have been the mainstay of secondary prevention of cervical cancer for decades; screening with a test for high-risk HPV, usually as a co-test with a Pap test, has been increasingly used during the past decade (2,3) . Recommended  \n* [https://www.cdc.gov/cancer/hpv/diagnosis-by-age.html](https://www.cdc.gov/cancer/hpv/diagnosis-by-age.html)  \nscreening intervals have increased, from annually to every 3 years (cytology only) or every 5 years (incorporating an HPV test) . In 2006, HPV vaccine was first recommended in the United States by CDC’s Advisory Committee on Immunization Practices to prevent cancers and other diseases caused by HPV†(2) . Routine vaccination was first recommended for girls and women; in 2011, boys and men were included in the vaccination program. Currently, routine vaccination is recommended for all children at age 11–12 years (may commence at age 9 years), with catch-up vaccination through age 26 years (2) . Since 2019, shared clinical decision-making has been recommended for consideration of vaccination of adults aged 27–45 years. Two doses of HPV vaccine are recommended if the series is started at age \u003C15 years; otherwise, 3 doses are recommended. Coverage with ≥1 HPV vaccine dose among adolescents aged 13–17 years steadily increased through 2021 then plateaued, with most recent coverage of 76.8% in 2023 (4) . CDC has monitored CIN2+ incidence since 2008 via the Human P","cbCaikoJOnFd4d3B","https://ap.wps.com/l/cbCaikoJOnFd4d3B","pdf",311309,"English","# Abstract\n# Introduction\n# Methods\n## Surveillance System\n## Populations and Screening Estimation","[{\"question\":\"What surveillance outcome does the HPV-IMPACT project track for cervical cancer prevention impact?\",\"answer\":\"It tracks the incidence of precancerous cervical lesions, defined as CIN2+ (CIN grades 2–3 and adenocarcinoma in situ) and CIN3+ (CIN grade 3 and AIS).\"},{\"question\":\"What were the reported changes in CIN2+ and CIN3+ rates from 2008 to 2022 for ages 20–24?\",\"answer\":\"Among screened women aged 20–24, rates decreased by 79% for CIN2+ and by 80% for CIN3+ during 2008–2022.\"},{\"question\":\"Which age group showed a decline in CIN3+ rates from 2008 to 2022 in addition to the 20–24 group?\",\"answer\":\"Women aged 25–29 years showed a 37% decrease in CIN3+ rates during 2008–2022.\"}]","Trends in Cervical Precancers Identified Through Population-Based Surveillance - Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008–2022 | PDF",1790175875,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/685b17a0fcbfba63d3db072072ca3cf1.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df2479a37f50087cb51f0531ec4b82bf.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/840d8abe53e7661114ac1fbe1863d473.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10c9d527fbb785fdafae41bf72cbc0df.webp",980,1268]